Compare SOAR & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | AIMD |
|---|---|---|
| Founded | 2021 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.6M |
| IPO Year | 2021 | 2008 |
| Metric | SOAR | AIMD |
|---|---|---|
| Price | $0.19 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.9M | 21.4K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 498.95 |
| 52 Week Low | $0.10 | $1.26 |
| 52 Week High | $4.36 | $4.44 |
| Indicator | SOAR | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 49.45 |
| Support Level | $0.13 | $1.33 |
| Resistance Level | $0.20 | $1.66 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 18.19 | 35.24 |
Volato Group Inc is an aviation technology company that connects travelers to private, on-demand flight access and develops proprietary software platforms for enterprise and operational applications. The company operates in a single operating and reportable segment, private aviation services. It operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.